Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$38.3 million.

  • Stoke Therapeutics' Net Income towards Common Stockholders fell 45.09% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 138.26%. This contributed to the annual value of -$88.7 million for FY2024, which is 15.38% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Net Income towards Common Stockholders of -$38.3 million as of Q3 2025, which was down 63.30% from -$23.5 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Net Income towards Common Stockholders registered a high of $112.9 million during Q1 2025, and its lowest value of -$38.3 million during Q3 2025.
  • For the 3-year period, Stoke Therapeutics' Net Income towards Common Stockholders averaged around -$13.0 million, with its median value being -$25.7 million (2024).
  • Data for Stoke Therapeutics' Net Income towards Common Stockholders shows a peak YoY increase of 527.99% (in 2025) and a maximum YoY decrease of 45.09% (in 2025) over the last 5 years.
  • Stoke Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then skyrocketed by 60.43% to -$10.7 million in 2024, then crashed by 45.09% to -$38.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$38.3 million for Q3 2025, versus -$23.5 million for Q2 2025 and $112.9 million for Q1 2025.